Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 International, Multicenter, Double-blind, Placebo-controlled Study of the Safety, Efficacy, and Tolerability of Intravenous Antegren (Natalizumab) in Subjects With Moderate to Severely Active Crohn's Disease

NCT00032799 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00032799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00032799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 International, Multicenter, Double-blind, Placebo-controlled Study of the Safety, Efficacy, and Tolerability of Intravenous Antegren (Natalizumab) in Subjects With Moderate to Severely Active Crohn's Disease
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2001
Completion date
September 30, 2003
Enrollment
905 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease